Inozyme Pharma (NASDAQ:INZY) Given New $11.00 Price Target at Wells Fargo & Company

Inozyme Pharma (NASDAQ:INZY - Get Free Report) had its price target decreased by Wells Fargo & Company from $14.00 to $11.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock.

A number of other research analysts have also weighed in on the company. Raymond James began coverage on Inozyme Pharma in a report on Thursday, December 12th. They issued an "outperform" rating and a $26.00 price objective on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $23.00 price target on shares of Inozyme Pharma in a report on Wednesday, November 6th. Wedbush restated an "outperform" rating and set a $12.00 price objective on shares of Inozyme Pharma in a research note on Friday. HC Wainwright increased their price objective on shares of Inozyme Pharma from $14.00 to $16.00 and gave the stock a "buy" rating in a research note on Friday. Finally, Piper Sandler lowered their price target on shares of Inozyme Pharma from $43.00 to $30.00 and set an "overweight" rating on the stock in a report on Monday. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $18.33.

Inozyme Pharma Stock Performance

INZY stock traded down $0.28 during trading on Monday, reaching $1.72. The company had a trading volume of 1,516,904 shares, compared to its average volume of 918,272. The company has a market cap of $110.49 million, a price-to-earnings ratio of -1.10 and a beta of 1.35. Inozyme Pharma has a twelve month low of $1.61 and a twelve month high of $7.80. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. The firm has a 50-day simple moving average of $2.96 and a 200-day simple moving average of $4.36.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.05. As a group, sell-side analysts expect that Inozyme Pharma will post -1.59 earnings per share for the current year.

Institutional Investors Weigh In On Inozyme Pharma

Institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company boosted its position in Inozyme Pharma by 14.4% during the second quarter. The Manufacturers Life Insurance Company now owns 21,427 shares of the company's stock worth $96,000 after purchasing an additional 2,690 shares in the last quarter. Jane Street Group LLC increased its position in shares of Inozyme Pharma by 7.5% in the third quarter. Jane Street Group LLC now owns 49,460 shares of the company's stock valued at $259,000 after buying an additional 3,443 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Inozyme Pharma by 11.0% during the 2nd quarter. American Century Companies Inc. now owns 57,100 shares of the company's stock worth $255,000 after buying an additional 5,673 shares during the period. OneDigital Investment Advisors LLC lifted its position in shares of Inozyme Pharma by 51.5% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 20,000 shares of the company's stock valued at $105,000 after buying an additional 6,800 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Inozyme Pharma by 31.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 28,928 shares of the company's stock worth $151,000 after acquiring an additional 6,851 shares in the last quarter. 88.30% of the stock is currently owned by institutional investors and hedge funds.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.